You are here

Articles

Posted on Thursday, May 4, 2023 - 12:32pm
Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include: Clinical papers
Posted on Saturday, March 4, 2023 - 3:52pm
Webstreams of the presentations and discussions from the iCMLf Forum 2022 that took place on December 9th 2022 in News Orleans (USA), are now available to view.
Posted on Monday, February 13, 2023 - 6:04pm
Please click on the link below access a selection of interesting articles on CML from peer-reviewed journals, including:
Posted on Saturday, July 23, 2022 - 1:49pm
Hear about current practices for third-line management of CML and get first-hand expert knowledge from:
Posted on Tuesday, June 28, 2022 - 11:15am
CML Highlights of EHA 2022 – Biological and clinical overview Join our two experts as they discuss key aspects of the CML presentations:
Posted on Saturday, March 26, 2022 - 10:18am
'Among challenges of TFR, it is also included the better identification of patients who have a high probability of relapsing compared with those who experience a successful TFR.
Posted on Tuesday, March 1, 2022 - 2:29pm
This review will present the current studies that are helping to increase our understanding of the biological factors (clinical and non-clinical, cellular, and molecular) that may determine TKI discontinuation success
Posted on Wednesday, February 23, 2022 - 10:45am
The evidence that vitamin D has important health benefits continued to increase in 2021. In particular, the benefits in reducing risk of SARS-CoV-2 infection and COVID-19 became more robust, as did those for CVD.
Posted on Monday, February 21, 2022 - 3:52pm
CML Advocates Network have provided a helpful summary of 63rd ASH meeting: CML abstracts and presentations 
Posted on Thursday, December 30, 2021 - 2:31pm
Discover how much vitamin D may be necessary to help you achieve your target vitamin D level.
Posted on Thursday, December 30, 2021 - 1:32pm
A. Hochhaus, M. Baccarani, .... R. Hehlmann 
Posted on Friday, December 3, 2021 - 1:14pm
In this issue of Blood, Cortes et al demonstrate that the optimal benefit-to-risk outcome for ponatinib-treated patients with chronic myeloid leukemia (CML) who had failed prior therapy was a starting dose of 45 mg,...
Posted on Wednesday, November 24, 2021 - 1:22pm
CML Highlights of the 63rd ASH Annual Meeting
Posted on Thursday, October 7, 2021 - 1:32pm
iCMLF Knowledge Centre  an interactive online resource providing educational content on CML patient management, options for molecular monitoring and